The New York Academy of Sciences, JAMA Oncology, and now a top-tier regulatory agency have thoroughly examined DCVax-L and validated its safety, efficacy, and significant therapeutic value. That level of recognition is not something that can be ignored or dismissed.
Furthermore, DCVax-L is protected through patents, regulatory safeguards, and proprietary technology, ensuring exclusivity and long-term commercial viability. Its manufacturing process is approaching automation, offering nearly unlimited scalability—a crucial factor for any treatment that aims to reach global markets.
Skeptics claiming that “no big pharma is interested in NWBO” are failing to acknowledge precedent. In biotech history, groundbreaking cancer immunotherapies have consistently drawn major acquisitions or partnerships from pharmaceutical giants:
--Merck acquired Viralytics for $394 million due to its oncolytic immunotherapy.
--Pfizer partnered with BioNTech for mRNA cancer vaccines, which later expanded beyond oncology.
--Gilead paid $11.9 billion for Kite Pharma, recognizing CAR-T therapies as the future of cancer treatment.
Given this track record, dismissing DCVax-L’s potential industry interest is absurd. Why wouldn’t big pharma want a first-in-class, proven effective, scalable cancer immunotherapy? Especially one validated across respected scientific, medical, and regulatory institutions?
The narrative that NWBO will face “endless dilution” also ignores the reality of biotech scaling. Companies with validated platforms and regulatory backing do not remain undervalued indefinitely. DCVax-L’s positioning suggests a future far stronger than penny-stock dilution fear-mongering implies.
Big pharma isn't ignoring this—they need NWBO/DCVax to save their own asses! It’s just a matter of timing.
"Against stupidity, we are defenseless"-- Dietrich Bonhoeffer, an anti-Nazi German Theologian, executed in the final days of the Nazi regime.
AI
Market Data 
Markets 
